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LETTER TO THE EDITORProphylactic and Preemptive
Therapy with Dasatinib after
Hematopoietic Stem Cell
Transplantation for
Philadelphia Chromosome-
Positive Acute Lymphoblastic
Leukemia
To the Editor:
Patients with Philadelphia chromosome-positive
acute lymphoblastic leukemia (Ph1 ALL) respond
poorly to conventional chemotherapy, with reported
long-term overall survival (OS) rates of10%. Recent
induction therapy based on tyrosine kinase inhibitors
(TKIs), alone or in combination, has achieved com-
plete response rates as high as 75%-95%; however,
these promising results are transitory, and effective
long-term maintenance strategies are lacking [1-3].
Although one retrospective study has suggested that
upfront therapy with imatinib might make it possible
to avoid consolidation therapy with allogeneic
hematopoietic stem cell transplantation (HSCT), the
presence of the Ph chromosome remains a primary
indication for HSCT. Indeed, patients treated with
HSCThave a 30%-60% increase in long-term survival
rates and a lower risk of relapse [4,5]. The presence of
minimal residual disease (MRD) after allogeneic or
autologous HSCT for Ph1ALL is highly predictive
of hematologic relapse.
Considerable research has been focused on investi-
gating the impact of TKIs, given either prophylacti-
cally or after detection of bcr-abl transcripts, on the
incidence of MRD, remission duration, and long-
term treatment outcome in patients with Ph1ALL
who underwent HSCT when in complete remission
[6]. The effect of the first-generation TKI imatinib
has been investigated in several studies, but the results
are somewhat contradictory [7-10]. Kebriaei et al. [10]
published the largest series of patients with Ph1ALL
treated with a first-generation TKI before and after
HSCT (31 cases), and found that neither pre-HSCT
nor post-HSCT imatinib administration had a signifi-
cant impact on transplantation outcome. In that study,
only 1 patient was treated with dasatinib (70 mg/day)
before and after HSCT. Overall, imatinib appears to
have very limited efficacy in treating hematologic re-
lapse of Ph1ALL, suggesting that second-generation652TKIsmay bemore suitable candidates for prophylactic
or preemptive treatment after HSCT. To the best of
our knowledge, no previous studies have investigated
the efficacy of dasatinib for this purpose.
The aimof this preliminary studywas to investigate
the efficacy, safety, and tolerability of post-HSCT da-
satinib in eradicating Ph1ALL and preventing relapse.
Between 2005 and 2011, 10 patients with Ph1ALL
(4 females and 6 males; median age, 41 years; range,
18-56 years) underwent autologous (n 5 2) or alloge-
neic (n 5 8) HSCT in our center. The patients repre-
sented 70% of the total number of patients with
Ph1ALL attending our center during that period.
Written informed consent was obtained from all pa-
tients, and the treatment schedule was approved by
the local Ethical Committee. The median follow-up
was 17 months post-HSCT. Patient characteristics
are summarized in Table 1.
Both qualitative and quantitative PCR assays were
used to detect and estimate the levels of bcr-abl tran-
scripts. mRNA was extracted from peripheral blood
using the EXTRAzol Kit, and synthesis of cDNA
was performed with the RT-Kit Plus (both from
Nanogen Advanced Diagnostics, Turin, Italy). Quali-
tative detection of the t(9:22) translocation (variants
P190, P210, and P230) was done using the Philadel-
phia Oligomix Alert Kit, and detection and measure-
ment of cDNA of bcr-abl transcripts was performed
using the PHILADELPHIA P190 Q-PCR Alert
AmpliMIX and PHILADELPHIA P210Q-PCRAlert
AmpliMIX Kits (all from Nanogen Advanced Diag-
nostics).
The p190 (e1a2) and p210 (b2a2 or b3a2) bcr-abl
transcripts were expressed in 80% and 20% of the pa-
tients, respectively. One-half of the patients had cyto-
genetic aberrations other than the classic t(9;22)
translocation. Nine patients received induction ther-
apy with TKIs: 4 with dasatinib 140 mg and 5 with im-
atinib 600 mg. One patient received induction therapy
based on chemotherapy alone (daunorubicin, vincris-
tine, and asparaginase). After induction, patients re-
ceived consolidation with high-dose cytarabine and
mitoxantrone (HAM) or modified hyper-CVAD (cy-
clophosphamide, vincristine, doxorubicin, methotrex-
ate, and cytarabine). Before HSCT, all patients
achieved a complete hematologic and cytogenetic re-
sponse. Four of the patients considered to be in com-
plete cytogenetic remission still had detectable MRD.
Two patients in first completemolecular remission
underwent autologous HSCT after a conditioning
regimen based on alkeran 200 mg/m2. The remaining
8 patients (4 in complete molecular remission)
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Biol Blood Marrow Transplant 18:652-654, 2012 653Letter to the Editorunderwent allogeneic HSCT after a fully myeloabla-
tive conditioning regimen consisting of total body irra-
diation plus cyclophosphamide (4 patients) or
treosulphan, fludarabine, and thiotepa (4 patients).
The graft source was an HLA-matched sibling donor
in 2 patients, an HLA-matched unrelated donor in 4
patients, and an HLA-haploidentical donor in 2 pa-
tients. Full donor stem cell engraftment was docu-
mented in all patients. Short-term methotrexate and
cyclosporin A therapy was provided for graft-versus-
host disease (GVHD) prophylaxis. One of the 8 pa-
tients who underwent allogenic HSCT received
a second allograft from another unrelated donor based
on cytogenetic evidence of relapse after the first
HSCT. Two patients developed acute grade II
GVHD followed by mild chronic GVHD. After
HSCT, MRD was still detectable in 3 patients. Two
of these patients were MRD-positive before HSCT,
and 1 patient became MRD-positive after HSCT
(Table 1). Therapy with dasatinib was started at a me-
dian time of 113.5 days after transplantation (range,
49-270 days). Drug doses ranged between 50 mg and
100 mg daily, according to tolerability and compli-
ance. Patients with grade 1 or lower toxicity according
to National Cancer Institute CommonToxicity Crite-
ria, version 4.0 (NCI-CTC) were treated with 100 mg/
day. In patients with grade 2 NCI-CTC, the dose was
temporarily reduced to 50 mg/day. In patients with
grade 3 NCI-CTC, the drug should be withheld and
subsequently reintroduced at 50 mg/day if the grade
drops to 1 or lower. If these patients again present toxi-
city greater than grade 1, then treatment with dasatinib
definitely should be stopped. Treatment also must
be interrupted in patients presenting with grade 4
NCI-CTC. Four of our patients developed grade 2
hematologic toxicity (neutropenia and thrombocyto-
penia), and 2 patients developed grade 1-2 nonhemato-
logic toxicity (diarrhea/pleural effusion).Monitoring of
cyclosporin A serum levels did not reveal any apparent
interactions with dasatinib. Two patients with the
kinase domain mutations T315I and E255K (highly
resistant and resistant to imatinib, dasatinib, nilotinib,
and bosutinib, respectively) died of ALL progression
at 16 and 18 months after HSCT (Table 1). During
maintenance treatment with dasatinib, MRD was neg-
ative in all 8 surviving patients, including 2 patients
testing positive after HSCT. All patients are still re-
ceivingmaintenance therapy with dasatinib, with ame-
dian duration of 15 months (range, 3-75 months).
Median OS since diagnosis is currently 22 months
(range, 8-87 months).
The presence of MRD both before and early after
HSCT is indicative of a poor prognosis. Posttrans-
plantation maintenance therapy with imatinib has
not yielded the desired results, and alternative ap-
proaches are needed to prevent hematologic relapse.
Dasatinib has a 325-fold greater potency than imatinib
654 Biol Blood Marrow Transplant 18:652-654, 2012Letter to the Editoragainst cells with unmutated bcr-abl and is effective
against several bcr-abl mutations that confer resistance
to imatinib [11]. This molecule is also capable of deter-
mining molecular remission in patients with Ph1ALL
and in Europe has been approved as second-line
therapy for patients who fail previous therapy [2,3].
In vitro studies have shown that dasatinib exerts
a more potent inhibitory action on c-kit and
PDGFR-ß (IC50 values of 5 and 28 nM, respectively,
compared with imatinib with IC50 values of 100 and
30 nM, respectively). It is possible that these
immunomodulating properties also may contribute
to reducing the risk of GVHD [12].
Based on our research results, dasatinib appears to
be highly effective in preventing molecular relapse and
eradication of Ph1ALL after HSCT. In view of the
lack of guidelines in the literature and the poor out-
come of relapsed Ph1ALL, we intend to continue da-
satinib treatment until patients achieve 5-year
complete molecular remission after HSCT. Although
the data presented here are very encouraging, larger
randomized clinical trials are needed to investigate
the long-term safety and efficacy of dasatinib, as well
as its eventual role in promoting resistant kinase do-
main mutations.REFERENCES
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